This Is MS Multiple Sclerosis Community: Knowledge & Support

CHMP gives positive opinion for extended indication for Rebif® for patients with early signs Of MS



Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for its variation application to extend the indication of Rebif (interferon beta-1a), its leading treatment for relapsing forms of multiple sclerosis (MS).

The positive CHMP opinion is for the use of Rebif 44 micrograms three times weekly in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1901

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis